Abatacept
Costimulation is the second signal a T cell requires before it can be fully activated, and abatacept blocks it. Depriving T cells of that signal dampens the overactive immune response driving inflammation and tissue damage in autoimmune disease, an approach upstream of the cytokine-directed biologics. Rheumatoid arthritis, psoriatic arthritis and juvenile idiopathic arthritis are the conditions treated, with administration by intravenous infusion or weekly subcutaneous injection. Because the drug suppresses T-cell activation, live vaccines are avoided during treatment and patients are monitored for signs of infection. The product is a protein therapeutic whose development has reached the final clinical phase.
A biologic medication that dampens an overactive immune response by blocking a signal that activates T cells, which are the immune cells responsible for causing inflammation and tissue damage in autoimmune diseases. It is used for conditions such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, and is given either as an intravenous infusion or a weekly subcutaneous injection. Patients taking it should avoid live vaccines and be monitored for signs of infection.
치료 영역
작용 기전
A soluble CTLA-4-Ig fusion protein. Abatacept binds CD80 and CD86 on antigen-presenting cells, preventing them from engaging CD28 on T cells. Without that costimulatory second signal the T cell is only partially activated, and the downstream cytokine release that drives synovial inflammation and joint destruction is damped.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
A soluble CTLA-4-Ig fusion protein. Abatacept binds CD80 and CD86 on antigen-presenting cells, preventing them from engaging CD28 on T cells. Without that costimulatory second signal the T cell is …
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
A biologic medication that dampens an overactive immune response by blocking a signal that activates T cells, which are the immune cells responsible for causing inflammation and tissue damage in autoimmune diseases. It is used for conditions such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, and is given either as an intravenous infusion or a weekly subcutaneous injection. Patients taking it should avoid live vaccines and be monitored for signs of infection.
A soluble CTLA-4-Ig fusion protein. Abatacept binds CD80 and CD86 on antigen-presenting cells, preventing them from engaging CD28 on T cells. Without that costimulatory second signal the T cell is only partially activated, and the downstream cytokine release that drives synovial inflammation and joint destruction is damped.
Yes, Abatacept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201823. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="abatacept"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/abatacept/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/abatacept/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/abatacept/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="abatacept"></drugfyi-drug>